A detailed history of Kbc Group Nv transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Kbc Group Nv holds 1,776 shares of BPMC stock, worth $229,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,776
Previous 2,723 34.78%
Holding current value
$229,920
Previous $241,000 5.39%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 08, 2025

SELL
$79.22 - $128.4 $75,021 - $121,594
-947 Reduced 34.78%
1,776 $228,000
Q1 2025

Apr 25, 2025

BUY
$86.69 - $115.63 $8,495 - $11,331
98 Added 3.73%
2,723 $241,000
Q4 2024

Jan 22, 2025

BUY
$82.48 - $101.39 $84,377 - $103,721
1,023 Added 63.86%
2,625 $229,000
Q2 2024

Jul 17, 2024

BUY
$85.18 - $108.78 $23,935 - $30,567
281 Added 21.27%
1,602 $173,000
Q4 2023

Feb 13, 2024

BUY
$43.96 - $92.84 $58,071 - $122,641
1,321 New
1,321 $122,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $7.73B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.